|[April 29, 2013]
Transgene: Promising Final Data from the Phase 2 HCVac Trial of TG4040 Presented at EASL 2013
STRASBOURG, France --(Business Wire)--
Transgene SA (Paris:TNG) (Euronext Paris: FR0005175080), a
biopharmaceutical company that develops targeted immunotherapy products
to treat major unmet medical needs in cancer and chronic infectious
diseases, announced final data of the Phase 2 HCVac trial of TG4040 for
the treatment of genotype 1 chronic hepatitis C (CHC) at an oral
presentation of the European Association for the Study of the Liver
(EASL) Congress in Amsterdam, the Netherlands.
Professor Heiner Wedemeyer, University of Hanover, Germany and Principal
Investigator of the HCVac trial, today presented the final data at EASL
and stated: "This trial is unique in the field of hepatitis C,
representing one of the largest randomized studies ever investigating an
immunotherapeutic product against a persistent infection. It is
remarkable that TG4040 induced a decline in HCV viral load and that
early response rates of standard therapy with peg-interferon alpha and
ribavirin were increased. In addition, very important general findings
were made that will help Transgene optimize the future clinical
development of TG4040."
This open label study evaluated in 153 randomized patients two schedules
of TG4040 in combination with PegIFNa2a (P) and ribavirin (R) versus P/R
alone (Arm A): Arm B with six TG4040 injections initiated 4 weeks after
P/R and pre-vaccination Arm C with thirteen TG4040 injections initiated
12 weeks before P/R.
The positive effect of TG4040 was seen with pre-treatment of TG4040 in
Arm C. The benefit of pre-treatment was observed as early as one week
after initiation of PEG-IFNa/RBV with a 40% improvement in decline of
mean HCV RNA viral load. The primary endpoint was met in Arm C with a
complete early viral response (cEVR) of 64% as compared to 30% in the
control arm (p=0.0037).
The virologic response was sustained over time with a SVR24 of 58% in
Arm C, compared to 48% in the control arm.
The key immunologic findings were that induction of MVA and HCV specific
T-cell responses were essentially seen in Arm C before the addition of
PEG-IFNa/RBV. The viral response seen in Arm C was observed in spite of
the development of anti-MVA responses.
Overall, safety was similar across the three arms (percentage of adverse
events and grade). The investigation of the four cases of severe blood
toxicity led to the conclusion of an exacerbation of IFN-known immune
side effects in patients with autoimmune predisposition (see press
release of 23rd April 2012).
Philippe Archinard, Chairman and Chief Executive Officer of Transgene,
stated: "Today's oral presentation at EASL once again verifies the
high level of scientific and medical interest in Transgene's
immunotherapy products. The final results of the HCVac study
demonstrated that a specific vectored immunotherapeutic can improve
treatment of CHC. While new treatment paradigms are currently emerging,
and are likely to enter the market as early as 2014, Transgene is
examining different opportunities for TG4040's future clinical
development. Given the results of our Phase 2 study, immunotherapy with
TG4040 may warrant further evaluation in combination with IFN-free
direct-acting antivirals treatment regimens once they are approved."
Transgene's TG4040 immunotherapeutic product is a recombinant vector
based on the MVA virus carrying and expressing three of the major
non-structural proteins (NS3, NS4 and NS5B) of the hepatitis C virus
("HCV"). The MVA vector is a highly attenuated strain of vaccinia virus,
which has been tested extensively in humans as a vaccine against
smallpox and is known to strongly stimulate innate and adaptive immune
responses to antigens.
About TG4040 Clinical Development Program
In this Phase 2 HCVac study, a total of 153 treatment-na�ve patients
were enrolled in 28 sites from Europe, the United States and Israel.
Patients were randomized in three arms: one control arm (48 weeks of
Peg-IFN/RBV) or one of the two experimental arms. In one experimental
arm, the TG4040 dosage (subcutaneous injections at the dose of 107
pfu) was administered six times and Peg-IFN/RBV was given as a 4 week
lead-in prior to the initiation of TG4040. In the other experimental
arm, the same TG4040 dosage was administered 13 times and Peg-IFN/RBV
was introduced twelve weeks after initiation of pre-treatment with
TG4040. The HCVac trial evaluated the efficacy and safety of these two
different schedules of TG4040 administration in combination with Peg-IFN
and RBV as compared to Peg-IFN/RBV alone.
Transgene (NYSE-Euronext: TNG), a member of the Institut M�rieux Group,
is a biopharmaceutical company. We create, develop and manufacture
targeted immunotherapeutics for the treatment of cancers and infectious
diseases. Our products are major technological breakthroughs that use
well tolerated viruses to indirectly or directly kill infected or
cancerous cells. Our four most advanced products have generated proof of
concept data in randomized clinical studies: in lung cancer (TG4010),
liver cancer (Pexa-Vec), hepatitis C (TG4040) and HPV-related cervical
lesions (TG4001). We have concluded strategic agreements for the
development of three of these products: an option agreement with
Novartis for the development of TG4010, an in-licensing agreement with
US-based Jennerex, Inc. to develop and market Pexa-Vec and a strategic
collaboration with EORTC to develop TG4001 in cancer of the oropharynx.
We also have a non-exclusive agreement with Sanofi/Genzyme for the
future commercial production of our products. Most of our 280 employees
are based in Strasbourg, France, and we have operations in Lyon, China
and the USA. Additional information about Transgene is available at www.transgene.fr.
Transgene Forward Looking Statements
This press release contains forward-looking statements notably referring
to plans for the future development of TG4040 as a treatment against
chronic hepatitis C, in combination with new treatments. These plans are
subject to changes and uncertainties and we could never be able to
develop, manufacture or sell TG4040 in the future. For further
information on the risks and uncertainties involved in the testing and
development of Transgene's product candidates, see Trangene's Document
de R�f�rence on file with the French Autorit� des march�s financiers on
its website at http://www.amf-france.org
and on Transgene's website at www.transgene.fr.
[ InfoTech Spotlight's Homepage ]